Neuroscience

NeuroStreet To Transform Trading Technology With Tickblaze Acquisition

Retrieved on: 
Thursday, April 4, 2024
Professional Services, Education, Technology, Software, Finance, Fintech, Training, Neuroscience, Acquisition, Python, Sales

NeuroStreet , a fintech and trading education leader, is poised to transform the trading tech landscape by acquiring TickBlaze , a cutting-edge hybrid trading platform known for its advanced technology tailored to discretionary and quantitative traders.

Key Points: 
  • NeuroStreet , a fintech and trading education leader, is poised to transform the trading tech landscape by acquiring TickBlaze , a cutting-edge hybrid trading platform known for its advanced technology tailored to discretionary and quantitative traders.
  • Sean Kozak, CEO of NeuroStreet , proudly announces the addition of TickBlaze: "Bringing TickBlaze into the NeuroStreet family marks a pivotal step in enhancing our trading solutions," says Kozak.
  • Experience the innovation at the intersection of trading technology and education with NeuroStreet's acquisition of TickBlaze.
  • NeuroStreet is a global fintech platform and educational ecosystem committed to providing cutting-edge trading technology and education to traders and financial institutions worldwide.

Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder

Retrieved on: 
Wednesday, April 3, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Alertness, Depression, EEG, Motivation, ClinicalTrials.gov, MDD, Patient, Neuroscience, Anhedonia, H3, Pleasure, Alto, Cognition, Safety, Pharmacokinetics, Pharmaceutical industry

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of its Phase 2 double-blind, single- and multiple-dose study to determine the pharmacodynamic effects of ALTO-203 in MDD patients as well as assess its safety, tolerability, and pharmacokinetics.

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of its Phase 2 double-blind, single- and multiple-dose study to determine the pharmacodynamic effects of ALTO-203 in MDD patients as well as assess its safety, tolerability, and pharmacokinetics.
  • The present study will evaluate these effects in patients with MDD to determine the potential of ALTO-203 as an antidepressant.
  • “In a Phase 1 study, ALTO-203 demonstrated an acute increase in positive emotion relative to placebo and across several dosage levels.
  • This Phase 2 study consists of two sequential double-blind, placebo-controlled treatment periods and examines two doses of ALTO-203 and placebo given as monotherapy in patients with MDD.

Indivi to Collaborate with Biogen to Advance Digital Health Technology and Digital Biomarkers for Parkinson's Disease

Retrieved on: 
Tuesday, March 26, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Neurology, Multiple sclerosis, Biomarker, Neuroscience, Parkinson's disease, Biogen, Safety, LUMA, Medtech, Medical imaging

Indivi, a leading MedTech company headquartered in Basel, Switzerland, has entered into an agreement with Biogen to advance digital health technology and develop digital biomarkers for Parkinson's disease.

Key Points: 
  • Indivi, a leading MedTech company headquartered in Basel, Switzerland, has entered into an agreement with Biogen to advance digital health technology and develop digital biomarkers for Parkinson's disease.
  • As part of the agreement, Biogen will licence KonectomTM to Indivi, a smartphone-based digital biomarker platform that assesses neurological functions remotely for more precise, frequent measurement of disease evolution.
  • In addition, Biogen and Indivi aim to develop and validate novel digital endpoints in Parkinson’s disease as well as explore additional disease areas for endpoint development leveraging KonectomTM.
  • Indivi uses advanced computational and statistical modelling methods to potentially yield more precise measures of progression of Parkinson’s disease with improved signal-to-noise properties.

Bioelectronic medicine Feinstein Institutes researchers elected to AIMBE College of Fellows

Retrieved on: 
Monday, March 25, 2024
Health, Health Insurance, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Vagus nerve, Metabolism, Interdisciplinarity, Biomedical engineering, Brain, Sepsis, Rheumatoid arthritis, Medicine, Mevalonate pathway, Interface (computing), Communication, International Society, Disease, Paralysis, Diabetes, Education, Inflammation, Pulmonary hypertension, Nervous system, Class, PNAS, Cancer, Neuroscience, Doctor of Philosophy, AIMBE, Neuron, Inflammatory Bowel Diseases, Arthritis, Credit, Northwell Health, American Institute, Molecular medicine, Sensation, Infection, DRS, Immune system, Injury, Medical research, Inflammatory bowel disease, Biology, Multimedia, National academy, Government, ISAN, Medical device

The American Institute for Medical and Biological Engineering (AIMBE) has announced the election of two researchers from The Feinstein Institutes for Medical Research to the AIMBE College of Fellows Class of 2024 for their contributions to the fields of medical and biological engineering, and particularly the field of bioelectronic medicine.

Key Points: 
  • The American Institute for Medical and Biological Engineering (AIMBE) has announced the election of two researchers from The Feinstein Institutes for Medical Research to the AIMBE College of Fellows Class of 2024 for their contributions to the fields of medical and biological engineering, and particularly the field of bioelectronic medicine.
  • Valentin Pavlov, PhD , and Sangeeta Chavan, PhD , both professors in the Institute of Bioelectronic Medicine , were recognized in-person during the AIMBE Annual Event in Washington D.C..
  • Sangeeta Chavan (left) and Valentin Pavlov (right) have been elected to the AIMBE College of Fellows for advancing the fields of medical and biological engineering.
  • On behalf of the Feinstein Institutes and Northwell Health, we congratulate them.”
    The Feinstein Institutes for Medical Research is the global scientific home of bioelectronic medicine where medical researchers use modern technology to develop new device-based therapies to treat disease and injury.

Freestyle+ Announces New AI-Driven Improv Games Library

Retrieved on: 
Friday, March 22, 2024
Online, Consumer Electronics, Technology, Audio, Video, Professional Services, Mental Health, Seniors, Venture Capital, Artificial Intelligence, Electronic Games, Other Technology, Software, Entertainment, Consumer, Internet, Health, Music, Neuroscience, Mindless, Organization, Freestyle, AI, Video game

Freestyle+ today announced the limited release of Mindless games, their AI driven gaming library of neuroscience-backed, licensable digital games developed at the intersection of improvisation and music.

Key Points: 
  • Freestyle+ today announced the limited release of Mindless games, their AI driven gaming library of neuroscience-backed, licensable digital games developed at the intersection of improvisation and music.
  • Today, we’re announcing that we’ve done just that.”
    Features and benefits of the Mindless games include:
    Quick, creative, and collaborative mental fitness games designed to increase resilience & reduce self-judgment.
  • To sign up for updates, and to be first in line for early access to the Mindless games library, click here.
  • PRODUCT DESCRIPTION: The Mindless games library is a neuroscience-backed library of licensable, AI-driven digital games developed at the intersections of improvisation and music, aimed at improving the mental fitness of individuals and teams.

Dr. Gary K. Michelson and Alya Michelson Receive 2024 Humanitarian Award at the World Brain Mapping Foundation’s 21st Annual Gathering for Cure Awards

Retrieved on: 
Friday, March 22, 2024
Biotechnology, Health, Philanthropy, Oncology, Neurology, Mental Health, Health Technology, Research, Surgery, Foundation, Science, Brain mapping, Brain, Bowman-Biltmore Hotels, Innovation Park, Survival, ALS, Patient, Public policy, Immunology, Scientist, GFC, City, Neuroscience, Pioneer, Doctor of Philosophy, Mental health, Quality of life, Health policy, DSM-IV codes, Invention, Therapy, Intellectual property, Physician, M.D, State, Human

Inventor and philanthropist Dr. Gary K. Michelson and his wife Alya Michelson received the 2024 Humanitarian Award at the World Brain Mapping Foundation’s 21st Gathering for Cure (GFC) Awards Gala at the Biltmore Hotel in Los Angeles.

Key Points: 
  • Inventor and philanthropist Dr. Gary K. Michelson and his wife Alya Michelson received the 2024 Humanitarian Award at the World Brain Mapping Foundation’s 21st Gathering for Cure (GFC) Awards Gala at the Biltmore Hotel in Los Angeles.
  • The Humanitarian Award is given to individuals who have contributed significantly to survival and quality of life of patients across the Globe.
  • Previous recipients of the annual award include Dr. Anthony Fauci, Dr. Sanjay Gupta, and Ming Hsieh.
  • The World Brain Mapping Foundation focuses on helping wounded soldiers, brain and spine cancers, neurodegenerative disorders (Parkinson’s, Alzheimer’s, ALS, MS, etc.

Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Modafinil, Research, Depression, EEG, DSM-IV codes, Histamine, Brain, Regenerative medicine, CFO, NMDA, MDD, Partnership, Patient, CNS, CIAS, Neuroscience, CIRM, Anhedonia, IPO, PDE4, Overalls, IND, Biogen, Cognition, Johnson & Johnson, Central nervous system disease, Pharmaceutical industry

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress.

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress.
  • In January 2023, Alto reported positive results from a Phase 2a study in which patients with MDD and a cognitive biomarker signature were identified as more responsive to ALTO-100.
  • Alto is currently evaluating ALTO-100 in a 266-patient Phase 2b study in MDD patients characterized by the cognitive biomarker.
  • The increase was primarily attributable to costs associated with the Phase 2a clinical studies for ALTO-100 and ALTO-300, which were completed in 2023.

Meet Lydia: Alai Studios and Shaping Wealth Deploy Next-Gen AI to Usher in The Future of Financial Advice

Retrieved on: 
Tuesday, March 19, 2024
Technology, Personal Finance, Finance, Fintech, Other Technology, Professional Services, Software, Asset Management, Artificial Intelligence, Automation, UX, Learning, Intelligence, Empathy, Emotional intelligence, AI, Neuroscience, Psychology, Studio, CFA, Happiness, Cognition, Emotion, Management

Alai Studios and Shaping Wealth announced today the launch of Lydia , the future of financial advice.

Key Points: 
  • Alai Studios and Shaping Wealth announced today the launch of Lydia , the future of financial advice.
  • Alai and Shaping Wealth are jointly committed to a "human first" approach to financial guidance, ensuring that AI’s implementation into wealth management amplifies human brilliance.
  • "At Shaping Wealth, we're focused on transforming financial guidance's essence through behavioral science," said Shaping Wealth's Founder, Brian Portnoy, Ph.D., CFA.
  • Alai and Shaping Wealth are leading this shift by embracing the role that technology can play in humanity’s broader search for contentment and meaning.

Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion

Retrieved on: 
Monday, March 18, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, BMY, Psychosis, Bristol Myers Squibb, Citigroup, Growth, Schizophrenia, KarXT, Goldman Sachs, EPS, Patient, Neuroscience, Simpson Thacher & Bartlett, Acquisition, BMS, LLP, PRTC, Therapy, GAAP, Covington & Burling, Psychiatry, Bipolar I disorder, PDUFA, Pharmaceutical industry

The full text of the announcement from Bristol Myers Squibb is as follows:

Key Points: 
  • The full text of the announcement from Bristol Myers Squibb is as follows:
    Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience
    PRINCETON, N.J.-- Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Karuna Therapeutics, Inc. (“Karuna”).
  • With the acquisition's completion, Karuna shares have ceased trading on the Nasdaq Global Select Market and Karuna is now a wholly owned subsidiary of Bristol Myers Squibb (“BMS”).
  • “We are excited to expand our neuroscience portfolio as we welcome Karuna to Bristol Myers Squibb,” said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb.
  • Gordon Dyal & Co. and Citi are serving as financial advisors to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.

Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” Campaign

Retrieved on: 
Tuesday, March 19, 2024
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Psoriasis, Partnership, Patient, Neuroscience, Travel, Dermatology, Plaque, Bristol Myers Squibb, Humour, DSM-IV codes, Empowerment, System, Skin, Multimedia, FDA, Pharmaceutical industry

Award-winning actor Ted Danson, who lives with plaque psoriasis, teams up with Bristol Myers Squibb for the inspiring “ SO, Have You Found It?

Key Points: 
  • Award-winning actor Ted Danson, who lives with plaque psoriasis, teams up with Bristol Myers Squibb for the inspiring “ SO, Have You Found It?
  • View the full release here: https://www.businesswire.com/news/home/20240315988620/en/
    Actor Ted Danson and SOTYKTU patient Emily both living with moderate to severe plaque psoriasis.
  • (Photo: Bristol Myers Squibb)
    “Navigating plaque psoriasis is both deeply personal and often challenging for many patients,” acknowledged Carlos Dortrait, senior vice president and general manager of U.S. Immunology and Neuroscience at Bristol Myers Squibb.
  • Many with plaque psoriasis find themselves altering their lifestyles, sometimes avoiding social situations and personal connections.